This resolution expresses support for designating June 1 through June 7, 2026, as "Hidradenitis Suppurativa Awareness Week" to address the significant challenges posed by this chronic inflammatory skin disease. Hidradenitis Suppurativa (HS) affects approximately 3.3 million people in the United States, causing painful nodules, abscesses, and extensive scarring, often leading to profound physical and psychological distress. A major concern is that 75 percent of individuals with HS are misdiagnosed or diagnosed late, missing critical windows for early intervention and contributing to worsening disease progression and higher healthcare costs. The resolution emphasizes the urgent need for increased public and health professional awareness, promotion of timely and accurate diagnosis, and robust support for biomedical research to understand HS pathogenesis and develop new treatments. Ultimately, the designation seeks to accelerate the development of effective therapies, expand access to existing treatments, and advance policies that improve the overall quality of life for individuals living with HS and their caregivers.